enGene Holdings Inc. (ENGN)
NASDAQ: ENGN · Real-Time Price · USD
5.83
-0.13 (-2.18%)
Dec 20, 2024, 4:00 PM EST - Market closed
Company Description
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer.
Its lead product candidate is detalimogene voraplasmid, a non-viral monotherapy to treat non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) in patients that have been unresponsive to treatment with Bacillus Calmette-Guérin (BCG).
The company is based in Montreal, Canada.
enGene Holdings Inc.
| Country | Canada |
| Founded | 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 33 |
| CEO | Ronald H. Cooper |
Contact Details
Address: 4868 Rue Levy, Suite 220 Montreal, QC H4R 2P1 Canada | |
| Phone | 514 332 4888 |
| Website | engene.com |
Stock Details
| Ticker Symbol | ENGN |
| Exchange | NASDAQ |
| Fiscal Year | November - October |
| Reporting Currency | USD |
| CIK Code | 0001980845 |
| CUSIP Number | 46429B226 |
| ISIN Number | CA29286M1059 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Ronald H. W. Cooper | Chief Executive Officer and Director |
| Dr. Alex Nichols Ph.D. | Chief Strategy and Operations Officer |
| Dr. Anthony T. Cheung Ph.D. | Co-Founder and Chief Scientific Officer |
| John C. Brown D.Sc., FRSC, Ph.D. | Co-Founder and Member of Scientific Advisory Board |
| David Ryan Daws | Chief Financial Officer and Head of Business Development |
| Joan Connolly | Chief Technology Officer |
| Lee G. Giguere | Chief Legal Officer and Corporate Secretary |
| Sharon Tan | Vice President of Project Management and Head of Program Management |
| Dr. Raj Pruthi F.A.C.S., M.D., M.H.A. | Chief Medical Officer |
| Paul Erickson | Non-Executive Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 20, 2024 | 8-K | Current Report |
| Dec 20, 2024 | 424B5 | Filing |
| Dec 19, 2024 | 10-K | Annual Report |
| Dec 19, 2024 | 8-K | Current Report |
| Nov 21, 2024 | EFFECT | Notice of Effectiveness |
| Nov 21, 2024 | EFFECT | Notice of Effectiveness |
| Nov 21, 2024 | 424B3 | Prospectus |
| Nov 21, 2024 | 424B3 | Prospectus |
| Nov 18, 2024 | UPLOAD | Filing |
| Nov 18, 2024 | UPLOAD | Filing |